Sarepta Therapeutics reports a 3Q loss of $28.5 million
Story updates
09:16:31 PM UTC
SquawkNews
Sarepta Therapeutics reported third-quarter 2026 revenue of $381.4 million, down 5% year over year, and a GAAP operating loss of $9.0 million. Non-GAAP operating income was $22.9 million, while GAAP net loss was $28.5 million and adjusted diluted EPS was $0.13. The company raised the low end of its…
09:19:07 PM UTC
SquawkNews
Sarepta’s third-quarter revenue fell 5% year over year as lower ELEVIDYS sales, following safety events and a label update, outweighed growth in collaboration and other revenue. Net loss narrowed as lower research and development expenses, including the absence of prior-year Arrowhead milestone cos…